[Rapamycin inhibits the proliferation of prostate cancer cell line 22RV1 and activity of S6K1].

Objective: To explore the effects of rapamycin on the proliferation of prostate cancer cell line 22RV1 and the activity of S6K1.

Methods: Prostate cancer 22RV1 cells cultured in vitro were treated with rapamycin at the concentrations of 0, 50, 100, 200 and 400 nmol/L. The inhibition rate of the cells'proliferation was detected by MTT, and the activity of S6K1 was determined by liquid scintillation counting.

Results: Rapamycin significantly inhibited the proliferation of the prostate cancer 22RV1 cells and the activity of S6K1 in a dose- dependent manner, most obviously at 400 nmol/L (P<0.01).

Conclusion: Rapamycin can effectively suppress the proliferation of prostate cancer 22RV1 cells by regulating the expression of S6K1, the downstream protein of mammalian target of rapamycin (mTOR).